NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
As of and for the six months ended June 30, 2015
(Unaudited)
These unaudited Financial Statements and Notes should be read in conjunction with the audited financial statements and notes of Therapeutic Solutions International, Inc. as of and for the year ended December 31, 2014 included in its Annual Report on Form 10-K.
Note 1 Organization and Presentation Basis
The consolidated financial statements included herein have been prepared by Therapeutic Solutions International, Inc. (the Company), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). In the opinion of the management of the Company, these interim Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair presentation of the Companys financial position as of June 30, 2015 and the results of operations for the three and six months ended June 30, 2015 and 2014. Interim results are not necessarily indicative of results for a full year or for any future period.
The consolidated financial statements and notes included herein are presented as required by Form 10-Q, and do not contain certain information included in our audited financial statements and notes for the fiscal year ended December 31, 2014 pursuant to the rules and regulation of the SEC. For further information, refer to the financial statements and notes thereto as of and for the year ended December 31, 2014, and included in the Annual Report on Form 10-K on file with the SEC.
Therapeutic Solutions International, Inc. (the Company) was organized August 6, 2007 under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation organized September 21, 2010 (Splint). Splint is treated as the accounting acquirer in the accompanying financial statements.
Until April 28, 2014 the Company sold (directly and through distributors and sublicensees), in non-US countries, plastic intraoral devices known as Anterior Midpoint Stop Appliances (AMPSA Products)
.
Our customers were dentists and doctors. The AMPSA Products, which are used for the treatment and prevention of common neurological and temporomandibular disorders including migraine headaches, migraine pain and bruxism.
On April 28, 2014, we received a letter from Mr. J. Christopher Jaczko, a lawyer with the Procopio law firm in San Diego who represents Boyd Research, Inc. and related parties. In his letter, Mr. Jaczko notified us that our license to use the international patents for our AMPSA device, pursuant to our license agreement with his clients effective January 1, 2013, was terminated. The ostensible reason given was our failure to make certain unspecified payments due under the license agreement to his clients. We disputed the termination, but believed that the costs involved with litigating the termination of the New License was not in the best interest of the Company and its shareholders. Therefore, the Company moved in a new direction.
Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) ones immune system.
Activating ones immune system is now a well-accepted method to cure certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. On the other hand, inhibiting ones immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions.
TSI is developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The following outlines our relationships and divisions to focus on each of these programs:
Nutraceutical Division
TSI has been producing high quality nutraceuticals. Its flagship product, ProJuvenol
®
, is a proprietary mixture containing pterostilbene one of the most potent antioxidants known. TSOI filed a patent application for ProJuvenol
®
on 07-08-2015 titled: Augmentation of Oncology Immunotherapies by Pterostilbene Containing Compositions.
OmniBiome, Inc.,
(OMNI) - is a partially-subsidiary of TSI, incorporated in the State of Delaware on October 20, 2015, where the intellectual property surrounding probiotics is housed.
On November 18, 2015 the Company licensed to OmniBiome, Inc. certain intellectually property. The License agreement in its entirety may be read as an exhibit filed with Form 8K:
https://www.sec.gov/Archives/edgar/data/1419051/000107878215001890/f8k111715_ex10z1.htm
8
Licensed Patent Rights: Shall mean:
a. Patent Application Serial No. 62/213260 filed 9-02-2015 by Licensor.
b. Patent Application Serial No. 62/219020 filed 9-15-2015 by Licensor.
c. Patent Application Serial No. 62/232722 filed 9-25-2015 by Licensor.
1.
Initial Payment and Royalty Rate. For the licensed herein granted:
(a) Licensee agrees to pay a sign-up fee of $ 50,000.00.
(b) Licensee shall pay on earned royalty of Five Percent (5 %) of Licensees Gross Sales of Products and fifty percent (50%) of the sublicensing receipts.
(c) Licensee shall pay an annual minimum royalty fee of Fifteen Thousand Dollars ($15,000.00) for each licensed Product.
On December 4, 2015 the Company licensed to OmniBiome, Inc. certain intellectually property. The License agreement in its entirety may be read as an exhibit filed with Form 8K:
https://www.sec.gov/Archives/edgar/data/1419051/000107878215001971/f8k120815_ex10z2.htm
Licensed Patent Rights: Shall mean:
a. Patent Application Serial No. 62/194990 filed 7-21-2015 by Licensor.
1.
Initial Payment and Royalty Rate. For the licensed herein granted:
(a) Licensee agrees to pay a sign-up fee of $ 50,000.00.
(b) Licensee shall pay on earned royalty of Five Percent (5 %) of Licensees Gross Sales of Products and fifty percent (50%) of the sublicensing receipts.
(c) Licensee shall pay an annual minimum royalty fee of Fifteen Thousand Dollars ($15,000.00) for each licensed Product.
Current programs focus on the use of probiotics to prevent pre-term labor and on using probiotics to reverse periodontal disease. The Officers and Directors of the Company are also officers and Directors of Omni. As of July 20, 2016 TSI owns approximately 73.75% of the outstanding shares of Omni.
MolecuVax, Inc., (MVAX)
is a partially-owned subsidiary of TSI, incorporated in the State of Delaware on October 28, 2015, where the intellectual property surrounding immune-oncology is housed.
On February 8, 2015 the Company licensed to MolecuVax, Inc. certain intellectually property. The License agreement in its entirety may be read as an exhibit filed with Form 8K:
https://www.sec.gov/Archives/edgar/data/1419051/000107878216002281/f8k020816_ex10z1.htm
Licensed Patent Rights: Shall mean:
a. Patent Application Serial No. 62/258007 filed 11-20-2015 by Licensor.
1.
Initial Payment and Royalty Rate. For the licensed herein granted:
(a)
Licensee agrees to pay a sign-up fee of $ 100,000.00.
(b)
Licensee shall pay on earned royalty of Five Percent (5 %) of Licensees Gross Sales of Products and fifty percent (50%) of the sublicensing receipts.
(c) Licensee shall pay an annual minimum royalty fee of Thirty Thousand Dollars ($30,000.00) for each licensed Product.
9
The programs within MolecuVax include using exosomes derived from various immune cells to attack cancers as well as developing a cancer vaccine against cancers that express a certain protein unique to them. The Officers and Directors of the Company are also officers and Directors of MVAX. As of July 20, 2016 TSI owns approximately 21.5% of the outstanding shares of MVAX. Website: www.molecuvax.com.
Capo Therapeutics, Inc.
Capo Therapeutics, Inc., (CAPO) is a Delaware Corporation incorporated on March 28, 2016. The main focus of Capo Therapeutics is the development of an effective and safe vaccine against Alzheimers Disease (AD), one of the most devastating diseases of the century. Amyloid-beta (Ab) immunotherapy is considered to be a promising approach to reducing the level of Ab in the CNS of AD patients. However, data from the first clinical trial AN1792 indicated that vaccine should be designed not to induce autoreactive cellular responses and to be effective in the majority of the individuals from the risk groups. The Officers and Directors of the Company are also officers and Directors of CAPO. As of July 20, 2016 TSI owns approximately 6.5% of the outstanding shares of CAPO. Website: www.capotherapeutics.com.
Note 2 Significant Accounting Policies
Estimates
The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash
For the Statements of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents. There were no cash equivalents as of June 30, 2015 and 2014. Other assets include restricted cash of $10,000 that is used to secure a company credit card.
Inventory
Inventory consists of finished goods, and is stated at the lower of cost or market. The Company records cost of sales using the moving average cost method. There was no excess or obsolete inventory reserve at June 30, 2015 and December 31, 2014.
Depreciation and Amortization
Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement.
Intangible Assets
Intangible assets consisted primarily of intellectual properties such as proprietary nutrasecutal formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 Intangibles Goodwill and Other.
Long-lived Assets
In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the year ended December 31, 2014, the Company recognized an impairment charge of $210,000 for intangible assets.
10
Income Taxes
The Company accounts for income taxes under ASC 740
Income Taxes,
which codified SFAS 109,
Accounting for Income Taxes
and FIN 48
Accounting for Uncertainty in Income Taxes an Interpretation of FASB Statement No. 109.
Under the asset and
liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to
differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.
Going Concern
The Companys financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has experienced recurring losses over the past years which have resulted in accumulated deficits of approximately $2,822 thousand and a working capital deficit of approximately $184 thousand at June 30, 2015. These conditions raise uncertainty about the Companys ability to continue as a going concern.
The Companys ability to continue as a going concern is contingent upon its ability to secure additional financing, increase sales of its products and attain profitable operations. It is the intent of management to continue to raise additional capital.
However, there can be no assurance that the Company will be able to secure such additional funds or obtain such on terms satisfactory to the Company, if at all.
The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
Share Based Expenses
ASC 718
Compensation - Stock Compensation,
which codified SFAS 123, prescribes accounting and reporting standards for all stock-based payments awarded to employees, including employee stock options, restricted stock, employee stock purchase plans and stock appreciation rights. Such payments may be classified as either equity or liabilities. The Company should determine if a present obligation to settle the share-based payment transaction in cash or other assets exists. A present obligation to settle in cash or other assets exists if: (a) the option to settle by issuing equity instruments lacks commercial substance or (b) the present obligation is implied because of an entitys past practices or stated policies. If a present obligation exists, the transaction should be recognized as a liability; otherwise, the transaction should be recognized as equity. See also
Note 6 Equity Transactions.
The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50
Equity-Based Payments to Non-Employees,
which codified SFAS 123, and the Emerging Issues Task Force consensus in Issue No. 96-18,
Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring or in Conjunction with Selling, Goods or Services.
Measurement of share-based payment transactions with non-employees shall be based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction should be determined at the earlier of the performance commitment date or performance completion date. See also Note 6 Equity Transactions.
Recently Implemented Standards
The Company has implemented all new accounting pronouncements that are in effect that may impact its financial statements and does not believe that there are any new accounting pronouncements that have been issued that might have a material impact on its financial statements.
Note 3 Restricted Cash
Other non-current asset is a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2017, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.
11
Note 4 Equipment
The cost and accumulated depreciation of fixed assets and equipment at June 30, 2015 and December 31, 2014 are summarized below:
|
|
|
|
|
|
|
June 30, 2015
|
|
December 31, 2014
|
Computer Hardware
|
$
|
10,747
|
$
|
10,747
|
Office Furniture and Equipment
|
|
3,639
|
|
3,639
|
Shipping and Other Equipment
|
|
1,575
|
|
1,575
|
Total
|
|
15,961
|
|
15,961
|
Accumulated Depreciation
|
|
(15,961)
|
|
(15,961)
|
Property and Equipment, net
|
$
|
-
|
$
|
-
|
Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Depreciation expenses for the six months ended June 30, 2015 and year ended December 31, 2014 were $0 and $21,133, respectively.
Note 5 - Intangible Asset
On December 9, 2014 the Company contractually obtained the rights, title and interest in and to proprietary formulations for two nutritional supplement products known under the trade names: (a) T-Rx; and, (b) Vital Female; and, the purchase of all legal right, title and interest, in and to intellectual property including, but not limited to, Innovatives nutritional supplement product known under the trade name: Projuvenol. The Company issued 100,000,000 shares for this rights, title and interest. The fair value of the 100,000,000 shares of common stock of $210,000 has been recorded as intangible assets. On December 31, 2014, the Company performed an impairment test on the intellectual property, and the Company recorded an impairment of $210,000.
Note 6
Equity Transactions
Preferred Stock
The Company is authorized to issue 5,000,000 shares of $.001 par value preferred stock. The Company has not issued any preferred stock.
Common Stock
The Company is authorized to issue 699,999,999 shares of $.001 par value common stock. All shares have equal voting rights, are non-assessable, and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company.
On March 31, 2014, we issued 2,500,000 shares of common stock, valued at $.0035 per share, for consulting services.
On March 31, 2014, we issued 2,500,000 shares of common stock, valued at $.004 per share, for consulting services.
On March 31, 2014, we issued 2,000,000 shares of common stock, valued at $.0035 per share, for consulting services.
On March 31, 2014, we issued 5,000,000 shares of common stock, valued at $.004 per share, for legal services.
On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages.
On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages.
On September 30, 2014, we issued 26,562,500, shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages.
On September 30, 2014, we issued 21,476,435shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages.
On September 30, 2014, we issued 26,562,500 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages.
12
On September 30, 2014, we issued 21,250,000 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages.
On September 30, 2014, we issued 7,682,165 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages.
On December 9, 2014, we issued 100,000,000 shares of common stock, valued at $.0021 per share, in regard to a Material Definitive Agreement (Form 8-K filed on December 10, 2014).
On March 27, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On March 27, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for consulting services.
On April 1, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for consulting services.
On April 17, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On June 1, 2015, we issued 3,000,000 shares of common stock, valued at $.0026 per share, for consulting services.
On June 1, 2015, we issued 7,000,000 shares of common stock, valued at $.0025 per share, for legal services
On June 8, 2015, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On July 15, 2015, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On August 31, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On September 25, 2015, we issued 5,000,000 shares of common stock, valued at $.0046 per share, for consulting services.
On October 1, 2015, we issued 23,000,000 shares of common stock, valued at $.0063 per share, for consulting services.
On October 14, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On October 16, 2015, we issued 4,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On November 9, 2015, we issued 3,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On November 17, 2015, we issued 7,500,000 shares of common stock, valued at $.0041 per share, for consulting services.
On November 23, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On November 30, 2015, we issued 2,500,000 shares of common stock, valued at $.01 per share, for legal services.
On January 4, 2016, we issued 2,500,000 shares of common stock, valued at $.004 per share, for consulting services.
On January 22, 2016, we issued 2,500,000 shares of common stock, valued at $.0035 per share, for consulting services.
On February 1, 2016, we issued 2,500,000 shares of common stock, valued at $.003 per share, for consulting services.
On February 5, 2016, we issued 8,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
13
On February 22, 2016, we issued 5,451,000 shares of common stock, valued at $.003 per share, in regard to a License Agreement (Form 8-K filed on February 25, 2016).
On February 26, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On March 7, 2016, we issued 10,000,000 shares of common stock, valued at $.004 per share, for consulting services.
On March 21, 2016, we issued 100,800,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On May 2, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement and 1,000,000 shares of common stock, valued at $.0053 per share, for consulting services.
On May 26, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for consulting services.
On May 26, 2016, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On May 31, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for legal services.
Note 7 Discontinued Operation
On April 28, 2014, we received a letter from Mr. J. Christopher Jaczko, a lawyer with the Procopio law firm in San Diego who represents Boyd Research, Inc. and related parties. In his letter, Mr. Jaczko notified us that our license to use the international patents for our AMPSA device, pursuant to our license agreement with his clients effective January 1, 2013, was terminated.
The following are the summarized results of discontinued operations for the three and six months ended June 30, 2015 and 2014 and the Balance Sheet as of June 30, 2015and December 31, 2014:
|
|
|
|
|
|
|
|
|
|
|
For the Three Months ended June 30, 2015
|
|
For the Three Months ended June 30, 2014
|
|
For the Six Months ended June 30, 2015
|
|
For the Six Months ended June 30, 2014
|
Net international revenues
|
$
|
-
|
$
|
68,879
|
$
|
-
|
$
|
144,298
|
Cost of goods sold
|
|
-
|
|
(1,663)
|
|
-
|
|
(3,583)
|
Selling expenses
|
|
-
|
|
(1,997)
|
|
-
|
|
(4,578)
|
Bad debt
|
|
(4,670)
|
|
-
|
|
(4,670)
|
|
-
|
Obsolete inventory
|
|
(4,052)
|
|
-
|
|
(4,052)
|
|
-
|
Other income from discontinued operations
|
|
-
|
|
-
|
|
-
|
|
12,433
|
|
$
|
(8,772)
|
$
|
65,219
|
$
|
(8,772)
|
$
|
148,570
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2015
|
|
December 31, 2014
|
|
|
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
Accounts Receivable, net
|
|
-
|
|
46,845
|
|
|
|
|
Total assets of discontinued operations
|
$
|
-
|
$
|
46,845
|
|
|
|
|
Note 8 Related Party Transactions
On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages.
On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages.
On September 30, 2014, we issued 26,562,500, shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages.
14
On September 30, 2014, we issued 21,476,435shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages.
On September 30, 2014, we issued 26,562,500 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages.
On September 30, 2014, we issued 21,250,000 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages.
On September 30, 2014, we issued 7,682,165 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages.
As of June 30, 2015, the Company has advanced approximately $50,900 to the officers of the company. Additionally, the officers of the Company waived their monthly salary accrual from July 1, 2014 to December 31, 2014. The Company has accrued officer salaries of $90,000 and $132,500 and paid $18,000 and 10,192 for the six months ended June 30, 2015 and 2014, respectively.
Note 9 Litigation
The Company previously reported, on April 29, 2013 a former employee of the Company, Reid Jilek, sued the Company, its two directors and its three officers in San Diego County (California) Superior Court for breach of contract, retaliation, constructive discharge, failure to pay wages, failure to reimburse, conversion and fraudulent inducement. The complaint related to his employment agreement with the Company and his resignation which was effective in January 2013.
The trial was held in September 2014. On September 26, 2014 the Court ruled in favor of the Company and against all of Jileks claims, and ruled that the Company was the prevailing party, and therefore was entitled to recover its attorneys fees and costs from Jilek. The Company did not prevail in its cross-claims against Jilek. Jileks claims against the Companys directors and officers had previously been dismissed.
Note 10 Subsequent Events
On July 15, 2015, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On August 31, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On September 25, 2015, we issued 5,000,000 shares of common stock, valued at $.0046 per share, for consulting services.
On October 1, 2015, we issued 23,000,000 shares of common stock, valued at $.0063 per share, for consulting services.
On October 14, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On October 16, 2015, we issued 4,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On November 9, 2015, we issued 3,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On November 17, 2015, we issued 7,500,000 shares of common stock, valued at $.0041 per share, for consulting services.
On November 23, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On November 30, 2015, we issued 2,500,000 shares of common stock, valued at $.01 per share, for legal services.
On January 4, 2016, we issued 2,500,000 shares of common stock, valued at $.004 per share, for consulting services.
On January 22, 2016, we issued 2,500,000 shares of common stock, valued at $.0035 per share, for consulting services.
15
On February 1, 2016, we issued 2,500,000 shares of common stock, valued at $.003 per share, for consulting services.
On February 5, 2016, we issued 8,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On February 22, 2016, we issued 5,451,000 shares of common stock, valued at $.003 per share, in regard to a License Agreement (Form 8-K filed on February 25, 2016). Add detail payment schedule. Euro 250,000, Euro 275,000, Euro 300,000, Euro 375,000, and Euro 500,000
On February 26, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On March 7, 2016, we issued 10,000,000 shares of common stock, valued at $.004 per share, for consulting services.
On March 21, 2016, we issued 100,800,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On May 2, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement and 1,000,000 shares of common stock, valued at $.0053 per share, for consulting services.
On May 26, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for consulting services.
On May 26, 2016, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement.
On May 31, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for legal services.
On July 8, 2015, the United States Patent and Trademark Office (the USPTO) accepted U.S. Application No. 62/190170 titled Augmentation of Oncology Immunotherapies by Pterostilbene Containing Compositions.
On July 21, 2015, the United States Patent and Trademark Office (the USPTO) accepted U.S. Application No. 62/194990 titled Prevention of Pregnancy Complications by Probiotic Administration.
On September 02, 2015, the United States Patent and Trademark Office (the USPTO) accepted U.S. Application No. 62/213260 titled Preventative Methods and Therapeutic or Pharmaceutical Compositions for the Treatment or Prevention of Pregnancy Complications.
On September 15, 2015, the United States Patent and Trademark Office (the USPTO) accepted U.S. Application No. 62/219020 titled Diagnostic Methods For The Assessment Of Pregnancy Complications.
On September 25, 2015, the United States Patent and Trademark Office (the USPTO) accepted U.S. Application No. 62/232722 titled A Medical Device For Reducing The Risk Of Preterm-Labor And Preterm-Birth.
On October 20, 2015, OmniBiome, Inc, a partially-owned subsidiary of the Company, was incorporated in the State of Delaware.
On October 28, 2015, MolecuVax, Inc., a partially-owned subsidiary of the Company, was incorporated in the State of Delaware. On November 18, 2015, Therapeutic Solutions International, Inc. licensed certain intellectual property to OmniBiome, Inc., a partially-owned subsidiary of Therapeutic Solutions International, Inc., as follows:
(1)
Application No. 62/213260 titled Preventative Methods and Therapeutic or Pharmaceutical Compositions for the Treatment or Prevention of Pregnancy Complications covers utility of vaccines and various agents to alter pathological conditions in which the maternal immune system induces a process of inflammation that culminates in placental alterations leading to either fetal loss or preterm labor;
(2)
Application No. 62/219020 Diagnostic Methods For The Assessment Of Pregnancy Complications a cytokine-based diagnostic kit aimed at stratifying risk of preterm labor and other pregnancy associated complications; and
(3)
Application No. 62/232722 A Medical Device For Reducing The Risk Of Preterm-Labor And Preterm-Birth covering various medical devices aimed at immune modulating the cervical microenvironment in order to prevent preterm labor.
16
On November 20, 2015, the United States Patent and Trademark Office (the USPTO) accepted U.S. Application No. 62/258007 titled Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer.
On December 04, 2015, Therapeutic Solutions International, Inc. licensed certain intellectual property to OmniBiome, Inc., a partially-owned subsidiary of Therapeutic Solutions International, Inc., Application No. 62/194990 titled Prevention of Pregnancy Complications by Probiotic Administration.
On January 21, 2016, our Board of Directors elected Thomas E. Ichim, Ph.D, to fill a vacant seat on our Board of Directors.
On February 05, 2016, Therapeutic Solutions International, Inc. licensed certain intellectual property to MolecuVax, Inc., a partially-owned subsidiary of Therapeutic Solutions International, Inc., Application No. 62/258,007 titled Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer.
On April 27, 2016, the United States Patent and Trademark Office (the USPTO) accepted U.S. Application No. 62/327756 titled Augmentation Of Stem Cell Activity Using Pterostilbene And Compositions Containing Pterostilbene.